您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Nemonoxacin
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Nemonoxacin
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Nemonoxacin图片
CAS NO:378746-64-6
包装与价格：
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
TG-873870
产品介绍
Nemonoxacin (TG-873870) 是一种口服有效的强效广谱抗生素。Nemonoxacin 对不同种类的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌均具有较好的抑制活性。Nemonoxacin 可用于细菌感染和社区获得性肺炎的研究。
生物活性

Nemonoxacin (TG-873870) is an orally active and potent broad-spectrumantibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci,Neisseria gonorrhoeae, andHaemophilus influenza. Nemonoxacin can be used in the study ofbacterialinfections and community-acquired pneumonia[1][2][3].

IC50& Target

Bacterial[1][2][3].

体外研究
(In Vitro)

Nemonoxacin (0-5.51 μM; 24 h) shows good antibacterial activity in vitro[1].

Cell Viability Assay[1]

Cell Line:MSSA, MRSA
Concentration:0-5.51 μM (0-2048 μg/mL)
Incubation Time:24 h
Result:Inhibited MSSA and MRSA with MIC90values of 0.12 and 4 μg/mL.
体内研究
(In Vivo)

Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus,S. capitis,S. pneumoniaandE. faecalis) and Gram-negative (E. coli) isolates[2].
Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg)S. pneumonia0613 (PRSP) and (10, 20, 40, 80 mg/kg)K. pneumonia0607 infections in mouse pulmonary infection model[2].

Animal Model:CD-1 ICR mice (18-22 g; mouse systemic infection model)[2].
Dosage:1.6-4.0 mg/kg (S. aureusandS. capitisinfections), 2.4-10.0 mg/kg (S. pneumoniainfections), 5.0-22.6 mg/kg (E. faecalisinfections), 1.6-10.0 mg/kg (E. coliinfections)
Administration:Oral administration; 15 min and 6 h after infection
Result:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to againstS. aureusATCC 29213 (MSSA),S. aureus0705 (MRSA) andS. capitis0687 (levofloxacin-resistant MRSC), respectively.
Animal Model:CD-1 ICR mice (18-22 g; mouse pulmonary infection model)[2].
Dosage:2.5, 5, 10, 20 mg/kg (S. pneumonia0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia0607)
Administration:Oral administration; 6, 12 and 24 h after infection
Result:Significantly decreased colony counts in vivo.
Clinical Trial
分子量

371.43

Formula

C20H25N3O4

CAS 号

378746-64-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.